Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin

Kenji Kono, Chie Kojima, Nobuyuki Hayashi, Eiko Nishisaka, Katsuyuki Kiura, Shinobu Watarai, Atsushi Harada

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

We have developed poly(amidoamine) (PAMAM) dendrimers that have poly(ethylene glycol) (PEG) grafts at all dendrimer chain ends. To obtain PEG-modified dendrimers with sites for conjugation of anticancer drugs for this study, we prepared PAMAM G4 dendrimers that have a glutamic acid (Glu) residue at every chain end of dendrimer; PEG chains were attached to amino groups of Glu residues. We then combined the anticancer drug adriamycin to side chains of the Glu residues using an amide bond, [PEG-Glu(ADR)-G4], or hydrazone bond, [PEG-Glu(NHN-ADR)-G4]. For the dendrimers bearing adriamycin through amide linkage, adriamycin was released only slightly at pH 7.4 and 5.5. Although a negligible level of release occurred at pH 7.4 for dendrimers with adriamycin via hydrazone linkage, a remarkable extent of adriamycin release was induced at pH 5.5, which corresponds to the pH of late endosome. These adriamycin-bearing dendrimers showed much lower toxicity to HeLa cells than did free adriamycin. However, compared to PEG-Glu(ADR)-G4, PEG-Glu(NHN-ADR)-G4 exhibited 7 times higher cytotoxicity, suggesting the importance of pH-sensitive hydrazone linkage for high cytotoxicity. Furthermore, the PEG-modified dendrimers exhibited an equivalent level of toxicity to that of adriamycin-resistant SBC-3/ADR100 cells and their parent adriamycin-sensitive SBC-3 cells.

Original languageEnglish
Pages (from-to)1664-1675
Number of pages12
JournalBiomaterials
Volume29
Issue number11
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Bearings (structural)
Dendrimers
Ethylene Glycol
Doxorubicin
Polyethylene glycols
Glutamic Acid
Acids
Hydrazones
Cytotoxicity
Amides
Toxicity
Poly(amidoamine)
Endosomes
HeLa Cells
Grafts
Pharmaceutical Preparations

Keywords

  • Adriamycin
  • Chemotherapy
  • Dendrimer
  • Drug delivery
  • Poly(amidoamine)
  • Poly(ethylene glycol)

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. / Kono, Kenji; Kojima, Chie; Hayashi, Nobuyuki; Nishisaka, Eiko; Kiura, Katsuyuki; Watarai, Shinobu; Harada, Atsushi.

In: Biomaterials, Vol. 29, No. 11, 04.2008, p. 1664-1675.

Research output: Contribution to journalArticle

Kono, Kenji ; Kojima, Chie ; Hayashi, Nobuyuki ; Nishisaka, Eiko ; Kiura, Katsuyuki ; Watarai, Shinobu ; Harada, Atsushi. / Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin. In: Biomaterials. 2008 ; Vol. 29, No. 11. pp. 1664-1675.
@article{c40b827fbd294fe0a3b456e87b69c898,
title = "Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin",
abstract = "We have developed poly(amidoamine) (PAMAM) dendrimers that have poly(ethylene glycol) (PEG) grafts at all dendrimer chain ends. To obtain PEG-modified dendrimers with sites for conjugation of anticancer drugs for this study, we prepared PAMAM G4 dendrimers that have a glutamic acid (Glu) residue at every chain end of dendrimer; PEG chains were attached to amino groups of Glu residues. We then combined the anticancer drug adriamycin to side chains of the Glu residues using an amide bond, [PEG-Glu(ADR)-G4], or hydrazone bond, [PEG-Glu(NHN-ADR)-G4]. For the dendrimers bearing adriamycin through amide linkage, adriamycin was released only slightly at pH 7.4 and 5.5. Although a negligible level of release occurred at pH 7.4 for dendrimers with adriamycin via hydrazone linkage, a remarkable extent of adriamycin release was induced at pH 5.5, which corresponds to the pH of late endosome. These adriamycin-bearing dendrimers showed much lower toxicity to HeLa cells than did free adriamycin. However, compared to PEG-Glu(ADR)-G4, PEG-Glu(NHN-ADR)-G4 exhibited 7 times higher cytotoxicity, suggesting the importance of pH-sensitive hydrazone linkage for high cytotoxicity. Furthermore, the PEG-modified dendrimers exhibited an equivalent level of toxicity to that of adriamycin-resistant SBC-3/ADR100 cells and their parent adriamycin-sensitive SBC-3 cells.",
keywords = "Adriamycin, Chemotherapy, Dendrimer, Drug delivery, Poly(amidoamine), Poly(ethylene glycol)",
author = "Kenji Kono and Chie Kojima and Nobuyuki Hayashi and Eiko Nishisaka and Katsuyuki Kiura and Shinobu Watarai and Atsushi Harada",
year = "2008",
month = "4",
doi = "10.1016/j.biomaterials.2007.12.017",
language = "English",
volume = "29",
pages = "1664--1675",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "11",

}

TY - JOUR

T1 - Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin

AU - Kono, Kenji

AU - Kojima, Chie

AU - Hayashi, Nobuyuki

AU - Nishisaka, Eiko

AU - Kiura, Katsuyuki

AU - Watarai, Shinobu

AU - Harada, Atsushi

PY - 2008/4

Y1 - 2008/4

N2 - We have developed poly(amidoamine) (PAMAM) dendrimers that have poly(ethylene glycol) (PEG) grafts at all dendrimer chain ends. To obtain PEG-modified dendrimers with sites for conjugation of anticancer drugs for this study, we prepared PAMAM G4 dendrimers that have a glutamic acid (Glu) residue at every chain end of dendrimer; PEG chains were attached to amino groups of Glu residues. We then combined the anticancer drug adriamycin to side chains of the Glu residues using an amide bond, [PEG-Glu(ADR)-G4], or hydrazone bond, [PEG-Glu(NHN-ADR)-G4]. For the dendrimers bearing adriamycin through amide linkage, adriamycin was released only slightly at pH 7.4 and 5.5. Although a negligible level of release occurred at pH 7.4 for dendrimers with adriamycin via hydrazone linkage, a remarkable extent of adriamycin release was induced at pH 5.5, which corresponds to the pH of late endosome. These adriamycin-bearing dendrimers showed much lower toxicity to HeLa cells than did free adriamycin. However, compared to PEG-Glu(ADR)-G4, PEG-Glu(NHN-ADR)-G4 exhibited 7 times higher cytotoxicity, suggesting the importance of pH-sensitive hydrazone linkage for high cytotoxicity. Furthermore, the PEG-modified dendrimers exhibited an equivalent level of toxicity to that of adriamycin-resistant SBC-3/ADR100 cells and their parent adriamycin-sensitive SBC-3 cells.

AB - We have developed poly(amidoamine) (PAMAM) dendrimers that have poly(ethylene glycol) (PEG) grafts at all dendrimer chain ends. To obtain PEG-modified dendrimers with sites for conjugation of anticancer drugs for this study, we prepared PAMAM G4 dendrimers that have a glutamic acid (Glu) residue at every chain end of dendrimer; PEG chains were attached to amino groups of Glu residues. We then combined the anticancer drug adriamycin to side chains of the Glu residues using an amide bond, [PEG-Glu(ADR)-G4], or hydrazone bond, [PEG-Glu(NHN-ADR)-G4]. For the dendrimers bearing adriamycin through amide linkage, adriamycin was released only slightly at pH 7.4 and 5.5. Although a negligible level of release occurred at pH 7.4 for dendrimers with adriamycin via hydrazone linkage, a remarkable extent of adriamycin release was induced at pH 5.5, which corresponds to the pH of late endosome. These adriamycin-bearing dendrimers showed much lower toxicity to HeLa cells than did free adriamycin. However, compared to PEG-Glu(ADR)-G4, PEG-Glu(NHN-ADR)-G4 exhibited 7 times higher cytotoxicity, suggesting the importance of pH-sensitive hydrazone linkage for high cytotoxicity. Furthermore, the PEG-modified dendrimers exhibited an equivalent level of toxicity to that of adriamycin-resistant SBC-3/ADR100 cells and their parent adriamycin-sensitive SBC-3 cells.

KW - Adriamycin

KW - Chemotherapy

KW - Dendrimer

KW - Drug delivery

KW - Poly(amidoamine)

KW - Poly(ethylene glycol)

UR - http://www.scopus.com/inward/record.url?scp=38749150591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38749150591&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2007.12.017

DO - 10.1016/j.biomaterials.2007.12.017

M3 - Article

C2 - 18194811

AN - SCOPUS:38749150591

VL - 29

SP - 1664

EP - 1675

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 11

ER -